Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial).

Furosemide is the most commonly used loop diuretic in patients with heart failure (HF) despite data suggesting potential pharmacologic and antifibrotic benefits with torsemide. We investigated patients with HF in Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure who were discharged on either torsemide or furosemide. Using inverse probability weighting to account for the nonrandom selection of diuretic, we assessed the relation between choice of diuretic at discharge with 30-day mortality or HF hospitalization and 180-day mortality. Of 7,141 patients in the trial, 4,177 patients were included in this analysis, of which 87% (n = 3,620) received furosemide and 13% (n = 557) received torsemide. Torsemide-treated patients had lower ejection fraction and blood pressure and higher creatinine and natriuretic peptide level compared with furosemide. Torsemide was associated with similar outcomes on unadjusted analysis and nominally lower events on adjusted analysis (30-day mortality/HF hospitalization odds ratio 0.89, 95% CI 0.62 to 1.29, p = 0.55 and 180-day mortality hazard ratio 0.86, 95% CI 0.63 to 1.19, p = 0.37). In conclusion, these data are hypothesis-generating and randomized comparative effectiveness trials are needed to investigate the optimal diuretic choice.

Duke Scholars

Author Robert John Mentz Medicine, Cardiology

Author Victor Hasselblad Biostatistics & Bioinformatics, Division of Biostatistics

Author Adam David DeVore Medicine, Cardiology

Author Paul Wayne Armstrong Medicine, Cardiology

Author Kevin J. Anstrom Biostatistics & Bioinformatics, Division of Biostatistics

Author Adrian Felipe Hernandez Medicine, Cardiology

Author Christopher Michael O'Connor Medicine, Clinical Pharmacology